Advertisement

Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents

  • Türker AcarEmail author
  • Egemen Kaya
  • Mustafa Deniz Yoruk
  • Neslihan Duzenli
  • Recep Selim Senturk
  • Cenk Can
  • Lokman Ozturk
  • Canberk Tomruk
  • Yigit Uyanikgil
  • Frank J. Rybicki
Original Article
  • 66 Downloads

Abstract

Purpose

This study investigated the potential to reduce gadolinium levels in rodents after repetitive IV Gadodiamide administration using several chelating agents.

Materials and methods

The following six groups of rats were studied. Group 1: Control; Group 2: Gadodiamide only; Group 3: Meso-2,3-Dimercaptosuccinic acid (DMSA) + Gadodiamide; Group 4: N-Acetyl-l-cysteine (NAC) + Gadodiamide; Group 5: Coriandrum sativum extract + Gadodiamide; and Group 6: Deferoxamine + Gadodiamide. Brain, kidney, and blood samples were evaluated via inductively coupled plasma mass spectrometry. The brain was also evaluated histologically.

Results

Kidney gadolinium levels in Groups 4 and 5 were approximately double that of Group 2 (p = 0.033 for each). There was almost no calcification in rat hippocampus for Group 4 rodents when compared with Groups 2, 3, 5 and 6.

Conclusion

Our preliminary study shows that excretion to the kidney has a higher propensity in NAC and Coriandrum sativum groups. It may be possible to change the distribution of gadolinium by administrating several agents. NAC may lower Gadodiamide-induced mineralization in rat hippocampus.

Keywords

Gadolinium deposition Dimercaptosuccinic acid N-Acetyl-l-cysteine Coriandrum sativum Deferoxamine 

Notes

Acknowledgements

This study is dedicated to pharmacist Ozler Kiris who provided inspiration for this preclinical study passed away unexpectedly during preparation phase of this work. Additionally, our special appreciation extends to Elif Tetik Acar who continuously assisted us during manipulation of lateral tail vein of rodents.

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

Animal Experiment Ethics Committee of Ege University (ID: 2017-007).

References

  1. 1.
    Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging [Internet]. 2007;26(5):1190–7. https://doi.wiley.com/10.1002/jmri.21135. Accessed 6 Mar 2019
  2. 2.
    Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (London, England) [Internet]. 2000;356(9234):1000–1. https://linkinghub.elsevier.com/retrieve/pii/S0140673600026945. Accessed 4 Apr 2018
  3. 3.
    Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl [Internet]. 2006;21(4):1104–8. https://academic.oup.com/ndt/article/21/4/1104/1932577/Gadolinium-a-specific-trigger-for-the-development. Accessed 4 Apr 2018
  4. 4.
  5. 5.
    Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology [Internet]. 2014;270(3):834–41. https://pubs.rsna.org/doi/10.1148/radiol.13131669. Accessed 4 Apr 2018
  6. 6.
    Medicines Agency E. PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations. 2017. https://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/03/WC500223209.pdf. Accessed 5 Apr 2018
  7. 7.
    Commissioner O of the. Safety Alerts for Human Medical Products-Gadolinium-based Contrast Agents (GBCAs): drug safety communication—retained in body; new class warnings. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm. Accessed 5 Apr 2018
  8. 8.
    Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann H-J. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 °C. Invest Radiol [Internet]. 2008. 43(12):817–2. https://www.ncbi.nlm.nih.gov/pubmed/19002053. Accessed 4 Apr 2018
  9. 9.
    Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology [Internet]. 2015;276(1):228–32. https://pubs.rsna.org/doi/10.1148/radiol.2015142690. Accessed 4 Apr 2018
  10. 10.
    Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images. Invest Radiol [Internet]. 2015;50(12):805–10. https://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004424-201512000-00001. Accessed 4 Apr 2018
  11. 11.
    Cao Y, Huang DQ, Shih G, Prince MR. Signal change in the dentate nucleus on T1-weighted mr images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol [Internet]. 2016;206(2):414–9. https://www.ajronline.org/doi/10.2214/AJR.15.15327. Accessed 5 Apr 2018
  12. 12.
    Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology [Internet]. 2015;275(3):783–91. https://pubs.rsna.org/doi/10.1148/radiol.2015150337. Accessed 5 Apr 2018
  13. 13.
    Radbruch A. Are some agents less likely to deposit gadolinium in the brain? Magn Reson Imaging [Internet]. 2016;34(10):1351–4. https://linkinghub.elsevier.com/retrieve/pii/S0730725X16301412. Accessed 5 Apr 2018
  14. 14.
    McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, et al. Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology [Internet]. 2017;285(2):536–45. https://pubs.rsna.org/doi/10.1148/radiol.2017161594. Accessed 5 Apr 2018
  15. 15.
    Aposhian H V, Aposhian MM. meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol [Internet]. 1990;30(1):279–306. https://www.annualreviews.org/doi/10.1146/annurev.pa.30.040190.001431. Accessed 5 Apr 2018
  16. 16.
    Jones MM. New developments in therapeutic chelating agents as antidotes for metal poisoning. Crit Rev Toxicol [Internet]. 1991;21(3):209–33. https://www.ncbi.nlm.nih.gov/pubmed/2039595. Accessed 5 Apr 2018
  17. 17.
    Saxena G, Pathak U, Flora SJS. Beneficial role of monoesters of meso-2,3-dimercaptosuccinic acid in the mobilization of lead and recovery of tissue oxidative injury in rats. Toxicology [Internet]. 2005;214(1–2):39–56. https://linkinghub.elsevier.com/retrieve/pii/S0300483X05002714. Accessed 5 Apr 2018
  18. 18.
    Gürer H, Ozgünes H, Neal R, Spitz DR, Erçal N. Antioxidant effects of N-acetylcysteine and succimer in red blood cells from lead-exposed rats. Toxicology [Internet]. 1998;128(3):181–9. https://www.ncbi.nlm.nih.gov/pubmed/9750041. Accessed 5 Apr 2018
  19. 19.
    Guo M-Y, Wang H, Chen Y-H, Xia M-Z, Zhang C, Xu D-X. N-acetylcysteine alleviates cadmium-induced placental endoplasmic reticulum stress and fetal growth restriction in mice. PLoS One [Internet]. 2018;13(1):e0191667. https://www.ncbi.nlm.nih.gov/pubmed/29373603. Accessed 5 Apr 2018
  20. 20.
    Aga M, Iwaki K, Ueda Y, Ushio S, Masaki N, Fukuda S, et al. Preventive effect of Coriandrum sativum (Chinese parsley) on localized lead deposition in ICR mice. J Ethnopharmacol [Internet]. 2001;77(2–3):203–8. https://www.ncbi.nlm.nih.gov/pubmed/11535365. Accessed 5 Apr 2018
  21. 21.
    Velaga MK, Yallapragada PR, Williams D, Rajanna S, Bettaiya R. Hydroalcoholic seed extract of Coriandrum sativum (Coriander) alleviates lead-induced oxidative stress in different regions of rat brain. Biol Trace Elem Res [Internet]. 2014;159(1–3):351–63. https://link.springer.com/10.1007/s12011-014-9989-4. Accessed 5 Apr 2018
  22. 22.
    Verpooten GA, D’Haese PC, Boelaert JR, Becaus I, Lamberts L V, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transpl [Internet]. 1992;7(9):931–8. https://www.ncbi.nlm.nih.gov/pubmed/1328941. Accessed 5 Apr 2018
  23. 23.
    Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N, et al. Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology [Internet]. 2009;252(1):165–72. https://pubs.rsna.org/doi/10.1148/radiol.2522081399. Accessed 5 Apr 2018
  24. 24.
    Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus [Internet]. 2009;2(4):309–11. https://academic.oup.com/ckj/article-lookup/doi/10.1093/ndtplus/sfp042. Accessed 5 Apr 2018
  25. 25.
    Saxena G, Pathak U, Flora SJS. Beneficial role of monoesters of meso-2,3-dimercaptosuccinic acid in the mobilization of lead and recovery of tissue oxidative injury in rats. Toxicology [Internet]. 2005;214(1–2):39–56. https://linkinghub.elsevier.com/retrieve/pii/S0300483X05002714. Accessed 7 Apr 2018
  26. 26.
    Senol N, Nazıroğlu M, Yürüker V. N-acetylcysteine and selenium modulate oxidative stress, antioxidant vitamin and cytokine values in traumatic brain injury-induced rats. Neurochem Res [Internet]. 2014;39(4):685–92. https://link.springer.com/10.1007/s11064-014-1255-9. Accessed 7 Apr 2018
  27. 27.
    Oksay T, Nazıroğlu M, Ergün O, Doğan S, Özatik O, Armağan A, et al. N-Acetyl cysteine attenuates diazinon exposure-induced oxidative stress in rat testis. Andrologia [Internet]. 2013;45(3):171–7. https://doi.wiley.com/10.1111/j.1439-0272.2012.01329.x. Accessed 7 Apr 2018
  28. 28.
    Sreelatha S, Padma PR, Umadevi M. Protective effects of Coriandrum sativum extracts on carbon tetrachloride-induced hepatotoxicity in rats. Food Chem Toxicol [Internet]. 2009;47(4):702–8. https://linkinghub.elsevier.com/retrieve/pii/S0278691508007242. Accessed 7 Apr 2018
  29. 29.
    Zhang L, Hu R, Li M, Li F, Meng H, Zhu G, et al. Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci [Internet]. 2013;34(5):639–45. https://link.springer.com/10.1007/s10072-012-1090-1. Accessed 10 Apr 2018
  30. 30.
    Birka M, Wehe CA, Hachmöller O, Sperling M, Karst U. Tracing gadolinium-based contrast agents from surface water to drinking water by means of speciation analysis. J Chromatogr A [Internet]. 2016;1440:105–11. https://linkinghub.elsevier.com/retrieve/pii/S0021967316301662. Accessed 17 Apr 2018
  31. 31.
    Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. Anal Chim Acta [Internet]. 2013;764:1–16. https://linkinghub.elsevier.com/retrieve/pii/S0003267012017722. Accessed 17 Apr 2018
  32. 32.
    Smith APL, Marino M, Roberts J, Crowder JM, Castle J, Lowery L, et al. Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study. Radiology [Internet]. 2017;282(3):743–51. https://pubs.rsna.org/doi/10.1148/radiol.2016160905. Accessed 17 Apr 2018
  33. 33.
    Robert P, Violas X, Grand S, Lehericy S, Idée J-M, Ballet S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol [Internet]. 2016;51(2):73–82. https://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004424-201602000-00001. Accessed 17 Apr 2018
  34. 34.
    Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idée J-M, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats. Invest Radiol [Internet]. 2015;50(8):473–80. https://www.ncbi.nlm.nih.gov/pubmed/26107651. Accessed 17 Apr 2018
  35. 35.
    Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther [Internet]. 2016;10:465–81. https://www.ncbi.nlm.nih.gov/pubmed/26893541. Accessed 19 Apr 2018
  36. 36.
    Grant D, Johnsen H, Juelsrud A, Løvhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol [Internet]. 2009;50(2):156–69. https://journals.sagepub.com/doi/10.1080/02841850802637808. Accessed 11 Jan 2019
  37. 37.
    Thakral C, Abraham JL. Nephrogenic systemic fibrosis: histology and gadolinium detection. Radiol Clin North Am [Internet]. 2009;47(5):841–53. https://www.ncbi.nlm.nih.gov/pubmed/19744599. Accessed 12 Jan 2019

Copyright information

© Japan Radiological Society 2019

Authors and Affiliations

  • Türker Acar
    • 1
    • 6
    Email author
  • Egemen Kaya
    • 2
  • Mustafa Deniz Yoruk
    • 3
  • Neslihan Duzenli
    • 4
  • Recep Selim Senturk
    • 4
  • Cenk Can
    • 4
  • Lokman Ozturk
    • 3
  • Canberk Tomruk
    • 5
  • Yigit Uyanikgil
    • 5
  • Frank J. Rybicki
    • 6
  1. 1.Department of RadiologyUniversity of Health Sciences Bozyaka Education and Training HospitalIzmirTurkey
  2. 2.Department of PhysiologyEge University School of MedicineIzmirTurkey
  3. 3.Department of AnatomyEge University School of MedicineIzmirTurkey
  4. 4.Department of PharmacologyEge University School of MedicineIzmirTurkey
  5. 5.Department of HistologyEge University School of MedicineIzmirTurkey
  6. 6.Department of RadiologyUniversity of Ottawa Faculty of Medicine and The Ottawa Hospital Research InstituteOttawaCanada

Personalised recommendations